Skip to main content

Table 3 Concentrations of pneumococcal polysaccharide antigen serotype-specific IgG antibodies and opsonization indices in the RA treatment groups before and after 23-valent pneumococcal polysaccharide vaccination

From: Effect of abatacept on the immunogenicity of 23-valent pneumococcal polysaccharide vaccination (PPSV23) in rheumatoid arthritis patients

  

RA Control

MTX group

ABT/MTX group

n = 35

n = 55

n = 15

IgG GMCs (μg/ml)

6B

Before

0.84(0.58 to 1.11)

1.42(0.86 to 1.97)

1.19(0.73 to 1.65)

 

After

4.05(2.13 to 5.97)*

4.36(2.17 to 6.55)*

2.49(0.29 to 4.70)

 

Fold increase

2.38(1.41 to 5.62)

1.75(1.15 to 3.11)

1.19(0.77 to 2.44)

23F

Before

1.17(0.85 to 1.48)

1.79(1.33 to 2.25)

1.17(0.63 to 1.71)

 

After

11.61(4.16 to 19.07)*

7.41(4.48 to 10.33)*

3.78(1.87 to 5.70)*

 

Fold increase

3.36(1.85 to 9.42)

2.00(1.27 to 5.48)

1.96(1.15 to 5.99)

GM-OIs

6B

Before

17.24(10.96 to 23.53)

150.79(14.85 to 286.74)

43.33(0.15 to 86.51)

 

After

981.15(407.24 to 1555.05)*

584.29(270.29 to 898.28)*

1454.80(109.29 to 2800.31)*

 

Fold increase

10.22(1.92 to 79.48)

2.57(1.22 to 22.40)

14.65(2.96 to 193.79)

23F

Before

63.21(−6.79 to 133.20)

52.11(14.04 to 90.18)

178.13(−130.27 to 486.54)

 

After

713.49(307.97 to 1119.01)*

724.56(336.93 to 1112.19)*

880.73(−81.54 to 1843.01)*

 

Fold increase

6.86(2.50 to 27.14)

3.75(1.47 to 38.32)

2.50(1.33 to 35.74)

  1. IgG GMCs and GM-OIs are expressed as the mean (95 % CI). Fold increases are expressed as the median (IQR). Differences between pre- and post-vaccination GMCs of serotype-specific IgG were assessed using a paired-sample t test
  2. RA rheumatoid arthritis, MTX methotrexate, ABT abatacept, GMC geometric mean concentration, GM-OI geometric mean opsonization index, CI, confidence interval, IQR interquartile index
  3. *p < 0.05 compared with pre-vaccination IgG GMCs or GM-OIs